Qingfeng was listed as the "best industrial enterprise in China's pharmaceutical R & D product line"

On August 1, 2021 (the 38th) national pharmaceutical industry information annual conference was grandly opened in Jinan, Shandong Province. The conference officially released the list of the best industrial enterprises in China's pharmaceutical R&D product line in 2021. Qingfeng Pharmaceutical Group was listed on the list with its outstanding R&D and innovation driving force over the years!

In recent years, China has attached great importance to pharmaceutical innovation. Planning guidelines such as the outline of the national innovation driven development strategy and the guidelines for the development of pharmaceutical industry have put forward the objectives of the development of innovative drugs and set up special projects to promote the research and development of new drugs. In this context, the pattern of China's pharmaceutical market has been reshaped, the pharmaceutical industry has entered a new era of innovative R&D and the innovation vitality of domestic pharmaceutical enterprises has been released.

2021 is the first year of the 14th Five-Year Plan, which coincides with the historical intersection of the goals of the "two centenaries". Today, with the rapid iteration of new technologies, new products and new business forms, the industrial driving mode with innovation as the core is becoming more and more prosperous, and China's economy has entered a high-quality development stage. For pharmaceutical products, in order to realize the leap from a large pharmaceutical country to a powerful pharmaceutical country, we need the concerted efforts of all links of the industrial chain to promote the ecosystem in an all-round way.

Qingfeng pharmaceutical has been adhering to the R&D driven development strategy for many years, vigorously cultivating and introducing high-level technical talents, and has built high-end   R&D platforms such as national key laboratories, national enterprise technology centers and national postdoctoral research workstations.

At the same time, in Shanghai, Beijing, Hangzhou, Ganzhou and other places, a collaborative and efficient chemical innovative drug platform, high-value generic drug platform, natural drug innovation platform, pilot transformation platform and the world's largest Class A biomedical innovation professional accelerator have been built, forming a global and whole chain innovation and R&D system, and the level of new drug R&D has been synchronized with the world.

After more than 40 years of continuous R&D investment, the R&D pipeline of Qingfeng medicine has begun to take shape, and the R&D layout covers the fields of anti-tumor,   anti-infection,   central nervous system, digestion, cardio cerebrovascular and so on.

For the landing of various product pipelines, Qingfeng has planned and completed a relatively complete commercial production system, built a modern biomedical industrialization base integrating API (Active Pharmaceutical Ingredients) production, traditional Chinese medicine extraction and preparation production, and a unique landing and transformation platform of domestic pharmaceutical industry.

As a pharmaceutical enterprise driven by R&D and innovation, Qingfeng pharmaceutical will continue to adhere to the corporate mission of "continuously providing excellent services for human health", take patients as the center, take clinical needs as the guidance, adhere to the driving force of R&D and innovation, increase R&D investment, accelerate the transformation of R&D achievements, strive to provide patients with drugs with more clinical value and contribute Qingfeng strength to the health cause of the motherland!